Investors might want to bet on SELLAS Life Sciences Group, Inc. (SLS) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individua ...

SELLAS Life Sciences Group, Inc. (SLS) closed the last trading session at $5.3, gaining 16.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8.67 indicates a 63.6% upside potential.The mean estimate comprises three short-term price targets with a standard deviation of $2.31. While the lowest estimate of $6.00 indicates a 13.2% increase from the current price level, the most optim ...

Core Viewpoint - SELLAS Life Sciences (SLS) has experienced a significant stock increase of 346% over the past year, reaching $5.04, as its Phase 3 REGAL trial for the WT1-targeting cancer vaccine in acute myeloid leukemia (AML) patients approaches completion with 72 of the required 80 patient deaths recorded, indicating a potentially lower-than-expected mortality rate [2][6]. Company Overview - SELLAS Life Sciences is a late-stage clinical biopharmaceutical company focused on immunotherapy for various cancers, currently at a pivotal point due to its ongoing clinical trials [5]. - The company’s stock has seen a recent pullback of 13.4% in the past week, coinciding with the anticipation of Q4 earnings [6]. Trial Progress and Implications - The REGAL trial's slower-than-expected death rate is viewed positively, suggesting that the GPS vaccine may extend long-term survival for AML patients, with only 12 deaths among 66 at-risk patients recorded [3][8]. - The Independent Data Monitoring Committee (IDMC) has cleared the trial twice without modifications, indicating that the trial's two arms remain clearly separated [14]. Institutional Interest - Institutional ownership has surged from approximately 35-72 institutions prior to the interim results to over 171 institutions as of March 2026, with notable accumulation from firms like Vanguard and BlackRock [14]. Market Sentiment - Social sentiment around SELLAS has been very bullish, with scores ranging from 78 to 88 on platforms like Reddit, driven by the trial's progress and institutional accumulation [10][11]. - Analysts have set a consensus price target of $7.83, although the stock is trading near its 52-week high of $6.14, with the final REGAL readout expected by the end of 2026 [12][13].

Financial Position - As of December 31, 2025, SELLAS Life Sciences Group, Inc. estimates its unaudited cash and cash equivalents position at $71.8 million[4] - The company received approximately $26.5 million in proceeds from the exercise of common stock warrants after December 31, 2025[5] Share Information - As of January 7, 2026, the company had 170,282,026 shares of common stock outstanding[6]

– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events – – First Patient Dosed in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML – – Reported Positive Phase 2 Data of SLS009 in Relapsed/Refractory (r/r) AML at ASH 2025 – – $71.8 Million in Cash and Cash Equivalents as of December 31, 2025; Additional $42.6 Million in Proceeds Received in Q1 2026 to Date Through Warrant Exercises – NEW YORK, March 19, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________ FORM 10-K ________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-33958 SELLAS Life Sciences G ...

- Preclinical data show that SLS009 lowers the apoptotic threshold in AML cells by suppressing critical survival pathways -NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical data on SLS009 (tambiciclib), a potent, selective CDK9 inhibitor, will be presented in a poster ses ...

Core Insights - SELLAS Life Sciences Group has initiated a Phase 2 trial for SLS009 (tambiciclib), a CDK9 inhibitor, targeting newly diagnosed acute myeloid leukemia (AML) patients [1][2] - The trial aims to enroll approximately 80 patients, focusing on two cohorts with high unmet medical needs [2] - Topline data from the trial is expected in Q4 2026 [1] Group 1: Trial Details - The trial, designated NCT04588922, includes a predictive biomarker cohort and an early resistance cohort [4] - The predictive biomarker cohort targets newly diagnosed patients unlikely to benefit from standard venetoclax/azacitidine therapy based on molecular profiling [4] - The early resistance cohort includes patients who show no response after two cycles of aza/ven treatment [4] Group 2: Previous Results and Efficacy - In a completed Phase 2 trial for relapsed/refractory (r/r) AML, SLS009 combined with aza/ven met all endpoints, achieving an overall response rate (ORR) of 33% across all evaluable patients [3][5] - The ORR was 40% for the recommended 30mg BIW dose level, with specific subgroups showing even higher response rates: 44% in AML patients with myelodysplasia-related changes and 50% in ASXL1-mutated AML patients [5] - Median overall survival (mOS) for patients treated with the 30mg BIW dose was reported at 8.8 months, significantly higher than the 2.4 months with the best available therapy [5] Group 3: Company Overview - SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel therapies for various cancer indications [3] - The company's lead product candidate, GPS, targets the WT1 protein and has potential applications in both hematologic malignancies and solid tumors [3] - SLS009 is positioned as a potentially first and best-in-class CDK9 inhibitor, aiming to offer reduced toxicity and increased potency compared to existing options [3]

Core Viewpoint - SELLAS Life Sciences Group Inc. has experienced significant stock price appreciation, with over 200% increase in the last six months and approximately 45% year-to-date growth, indicating strong investor interest and potential for a short squeeze due to high short interest of 27.21% [1] ASH 2025 Data Presentation - In December 2025, SELLAS Life Sciences presented clinical data from its Phase 2 study of SLS009 combined with azacitidine and venetoclax for patients with relapsed or refractory acute myeloid leukemia, showing a 46% overall response rate and 29% achieving complete response [2] - The median overall survival for this patient population was significantly higher than the expected 2.6 months, reaching 8.9 months in the least pretreated cohort [3] Phase 3 REGAL Trial Update - An update on the Phase 3 REGAL trial was provided in December 2025, evaluating Galinpepimut-S as a maintenance therapy for AML patients after second complete remission, with the trial continuing without modification as per the Independent Data Monitoring Committee's recommendation [4] - As of December 26, 2025, the trial reported a pooled number of 72 events, approaching the 80 events required for final analysis [5] Technical Analysis - SELLAS Life Sciences is trading at $5.50, close to its 52-week high of $5.51, reflecting a 364.40% increase over the past year, with strong bullish momentum indicated by trading above key moving averages [6] - The stock is 31.6% above the 20-day simple moving average and 137.4% above the 200-day simple moving average, with a recent golden cross further supporting a bullish outlook [6] - Current technical indicators show an RSI of 72.66, suggesting potential overbought conditions, while the MACD indicates continued bullish momentum [7] Benzinga Edge Rankings - The Benzinga Edge scorecard for SELLAS Life Sciences highlights a bullish momentum score of 99.01, indicating the stock is significantly outperforming the broader market [8] - The stock's strong performance may attract more investors seeking growth opportunities in the biopharmaceutical sector [9]

Core Insights - Solaris Resources Inc. has received an option to acquire up to a 100% interest in a new portfolio of exploration areas adjacent to its Warintza Project in Ecuador, significantly expanding its operational footprint by approximately 40,000 hectares [2][3] Expansion of Exploration Areas - The newly optioned areas, referred to as Solaris 2, are expected to enhance the geological potential of the region, reinforcing the company's strategy to develop a world-class copper mining hub [3][4] - The areas are interpreted to host significant copper mineralization, characterized by widespread potassic alteration typical of large copper porphyry systems [6] Prospecting Activities - Early-stage prospecting results from Solaris 1 have identified compelling copper anomalies, with rock samples returning values up to 8.38% Cu, indicating strong exploration potential [6][11] - Over the past 16 months, the company has conducted 11 field prospecting expeditions, collecting more than 1,500 rock and soil samples, primarily focused on the Tinki South area [9][11] Community and Regulatory Engagement - Solaris is working collaboratively with the Shuar community of Tinkimints and relevant authorities to ensure compliance with Ecuadorian regulations and international best practices during exploration [12] - The company has established a prospecting agreement with the local community, which continues to provide support for its activities [12] Solaris 2 Concession Terms - The award of Solaris 2 areas includes an upfront payment of US$0.25 million, a proposed minimum exploration program of US$25 million over four years, and additional payments contingent on achieving certain milestones [13] - The commercial structure mirrors the Solaris 1 earn-in arrangement, indicating a consistent approach to investment in exploration [13] Development Strategy - Solaris is advancing a cohesive, district-scale development strategy that integrates its wholly owned Warintza property with the Solaris 1 and Solaris 2 optioned areas, enabling a multi-asset growth trajectory [14] - The company aims to leverage shared infrastructure and coordinated environmental and social management to enhance long-term value creation [14] Permitting and Feasibility Study - The Environmental Impact Assessment (EIA) for Warintza is in the final stages of review, with expectations for technical approval to be issued soon [16][17] - A Feasibility Study is underway, engaging leading international engineering firms to optimize mine design and infrastructure, with a focus on refining cost estimates and establishing a clear pathway toward construction [18][19]